Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Avantor, Inc.
Avantor sells the lab supplies, chemicals, equipment, and services that scientists and manufacturers need to research, test, and make products.
Avantor is the behind-the-scenes supplier for people in white lab coats. If you work in a biotech lab, a hospital, a university research building, or a factory making advanced electronics, odds are good that some of what you use every day — pipettes, chemicals, tubing, filters, protective gear, specialized equipment — came through Avantor.
The company does more than just ship boxes of gloves and beakers. It sells a huge catalog of laboratory and production products and materials, plus equipment and services, to customers in biopharma, healthcare, education, government, and advanced technology. The biopharma business is the big one: drugmakers rely on Avantor for the ultra-pure chemicals and single-use materials that go into making medicines, where a tiny contamination can ruin a batch worth millions. What makes Avantor valuable is not any single product. It is the combination of a giant catalog, deep technical know-how, and a promise that the stuff you order is consistent and traceable batch after batch. When a customer is producing a drug for human trials, they cannot just buy a cheaper jug of acid from a random supplier — they need documented quality, and Avantor sells that peace of mind along with the product. It competes with big distributors and specialty chemical suppliers, and it has spent years building out its own manufacturing and its own brands rather than only reselling others' goods.
The company, headquartered in Radnor, Pennsylvania, has grown partly by acquisition — it bought the lab-products maker VWR in 2017, which roughly doubled its size and turned it into a global distribution powerhouse. That scale is its strength: more products, more customers, more bargaining power. It is also its vulnerability, because it carries a hefty debt load from those deals, and its fortunes rise and fall with how much money biopharma companies are spending on research and manufacturing. When drugmakers tighten their belts, Avantor feels it.
Saved answer · last researched 15 Nov 2026